Long-term Prognosis of Patients With Sepsis After Immunotherapy

Sun Yat-sen University

Status: Not yet enrolling

Conditions: Long-term Effects of Thymosin Alpha 1 Treatment

Treatments: Drug: Thymosin Alpha1

Study type: Observational

Funder types: Other

Identifiers

NCT04901104

Long-term prognosis in sepsis

Details and patient eligibility

About

Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term outcomes (3 year mortality) of patients with sepsis after immunotherapy.

Based on the preliminary clinical study (NCT02867267), this study will conduct long-term follow-up for sepsis patients to provide data support for the long-term prognosis of immunotherapy.

Enrollment: 900 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Sepsis patients in the TESTS study Patients who discharged from hospital after recovery

Exclusion criteria

• None

Trial design

900 participants in 2 patient groups

thymosin α1 group

Description:

The patient was treated with thymosin α1 in sepsis

Treatment:

Drug: Thymosin Alpha1

placebo group

Description:

The patient was treated without thymosin α1 in sepsis